AI drug discovery startup Latch expands MTS team across chemistry and clinical science
kenbwork · x · 2026-11-17
Latch, an AI drug discovery company, is rapidly expanding its MTS team with open roles in chemistry, medicinal chemistry, molecular design, assay development, translational science, and clinical development/operations/data/trial design, citing impact from projects like GDPx biology, Fireworks SII, and Gemini 4 Hydrogen.
Related event: AI Drug Firm Latch Launches Major Hiring Spree(2 posts)→
More from Companies & People
- Jensen Huang admits on 60 Minutes he's "not easy to work for" — gajesh · 2026-11-17
- Google scientist: bad management and promo-driven engineering are tech's boiling frog — docmilanfar · 2026-11-17
- India's sovereign AI lab Sarvam slammed for mostly hosting Chinese models — itsOmSarraf_ · 2026-11-17
- OpenAI keeps charging a VIES-certified EU company 21% VAT it shouldn't owe, and support can't fix it — Creative_Strike8202 · 2026-11-17
- Nvidia director warns of 'irreplaceable talent' exodus if Huang isn't reinstated — TinfoilTricorn · 2026-11-17
- Data warehouse industry economics: fat-margin vendors, markup-driven integrators — huangyun_122 · 2026-11-17